Antifosfolipidsyndrom og graviditet

Karen Schreiber; Jacob Alexander Lykke; Jens Langhoff-Roos; Henriette Svarre Nielsen; Søren Jacobsen

Antifosfolipidsyndrom og graviditet

Translated title of the contribution: Antiphospholipid syndrome and pregnancy

Karen Schreiber, Jacob Alexander Lykke, Jens Langhoff-Roos, Henriette Svarre Nielsen, Søren Jacobsen

Department of Clinical Medicine

1 Citation (Scopus)

Abstract

Antiphospholipid syndrome (APS) is the association of antiphospholipid antibodies with thromboses and/or obstetric morbidity. Obstetric morbidity includes recurrent first trimester loss, stillbirth, intrauterine death, preeclam-psia, premature birth and fetal growth restriction. Although current treatment regimens including aspirin and low-molecular weight heparin have improved pregnancy outcomes, 30% of affected women have pregnancy complica-tions. Women with APS are therefore high-risk pregnancies who should be monitored in specialist centres according to international standards.

Translated title of the contribution	Antiphospholipid syndrome and pregnancy
Original language	Danish
Article number	V09150730
Journal	Ugeskrift for Laeger
Volume	178
Issue number	12
Pages (from-to)	2-5
ISSN	0041-5782
Publication status	Published - Jan 2016

Keywords

English Abstract
Journal Article

Cite this

@article{f3a75f0b776b48028a7d5caf465ab8a6,

title = "Antifosfolipidsyndrom og graviditet",

abstract = "Antiphospholipid syndrome (APS) is the association of antiphospholipid antibodies with thromboses and/or obstetric morbidity. Obstetric morbidity includes recurrent first trimester loss, stillbirth, intrauterine death, preeclam-psia, premature birth and fetal growth restriction. Although current treatment regimens including aspirin and low-molecular weight heparin have improved pregnancy outcomes, 30% of affected women have pregnancy complica-tions. Women with APS are therefore high-risk pregnancies who should be monitored in specialist centres according to international standards.",

keywords = "English Abstract, Journal Article",

author = "Karen Schreiber and Lykke, {Jacob Alexander} and Jens Langhoff-Roos and Nielsen, {Henriette Svarre} and S{\o}ren Jacobsen",

year = "2016",

month = jan,

language = "Dansk",

volume = "178",

pages = "2--5",

journal = "Ugeskrift for Laeger",

issn = "0041-5782",

publisher = "Almindelige Danske Laegeforening",

number = "12",

}

TY - JOUR

T1 - Antifosfolipidsyndrom og graviditet

AU - Schreiber, Karen

AU - Lykke, Jacob Alexander

AU - Langhoff-Roos, Jens

AU - Nielsen, Henriette Svarre

AU - Jacobsen, Søren

PY - 2016/1

Y1 - 2016/1

N2 - Antiphospholipid syndrome (APS) is the association of antiphospholipid antibodies with thromboses and/or obstetric morbidity. Obstetric morbidity includes recurrent first trimester loss, stillbirth, intrauterine death, preeclam-psia, premature birth and fetal growth restriction. Although current treatment regimens including aspirin and low-molecular weight heparin have improved pregnancy outcomes, 30% of affected women have pregnancy complica-tions. Women with APS are therefore high-risk pregnancies who should be monitored in specialist centres according to international standards.

AB - Antiphospholipid syndrome (APS) is the association of antiphospholipid antibodies with thromboses and/or obstetric morbidity. Obstetric morbidity includes recurrent first trimester loss, stillbirth, intrauterine death, preeclam-psia, premature birth and fetal growth restriction. Although current treatment regimens including aspirin and low-molecular weight heparin have improved pregnancy outcomes, 30% of affected women have pregnancy complica-tions. Women with APS are therefore high-risk pregnancies who should be monitored in specialist centres according to international standards.

KW - English Abstract

KW - Journal Article

M3 - Tidsskriftartikel

C2 - 26815583

SN - 0041-5782

VL - 178

SP - 2

EP - 5

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

IS - 12

M1 - V09150730

ER -

Antifosfolipidsyndrom og graviditet

Abstract

Keywords

Fingerprint

Cite this